• Augmedics

  Participated · Series C · Mar 2021

  Augmedics develops an AR-based navigation platform (branded Xvision) combining custom hardware and software to display digitized CT scans from a surgeon’s perspective. Its system, FDA-cleared in 2019 and commercially deployed in 2020, has been used in over 4,000 procedures and is installed in more than 70 U.S. hospitals. The platform can replace fluoroscopy in some non-invasive procedures and provides continuous intraoperative spine visualization in more invasive operations. The company emphasizes purpose-built hardware optimized for surgical use rather than off-the-shelf AR gear. Management plans to use new funding to build the next generation of the platform and accelerate commercial development while remaining focused on spinal applications. It has also received inbound interest for extensions into other musculoskeletal and cranial procedures that use CT/MRI imaging. Augmedics develops the xvision Spine System, the first and only FDA‑cleared augmented reality surgical image guidance system that lets surgeons visualize 3D spinal anatomy and navigate instruments while looking directly at the patient. The company received FDA 510(k) clearance in December 2019 and began U.S. sales in the second half of 2020. By year-end 2020 the system had been used in over 250 spinal surgeries. Augmedics plans to commercialize more broadly across the U.S. and into OUS markets, pursue CE certification for Europe, develop next‑generation products, and expand to new indications. Financially, the company has raised $63 million to date following a recent $36 million Series C and an earlier $21 million Series B. Augmedics develops the xvision Spine (XVS), an augmented reality surgical image-guidance system that enables surgeons to visualize a patient’s 3D spinal anatomy during surgery. XVS is designed to let surgeons accurately navigate instruments and implants while looking directly at the patient rather than a remote screen. The company received FDA 510(k) clearance and launched XVS in the U.S. in December 2019. The system is being used in renowned hospitals and surgical centers in the U.S. In June 2020 Augmedics completed a $15M Series B round that included staff investment and SAFE conversions. Leadership cited in the article includes founder and CEO Nissan Elimelech and President and CCO Tim Murawski. Augmedics develops the ViZOR, an augmented-reality surgical visualization system that projects a 3D image of a patient’s spine onto a surgeon’s retina in real time using proprietary see-through AR optics. The ViZOR is intended initially for minimally invasive spine surgeries to reduce operative time, radiation exposure and unnecessary repeat operations or hospitalizations. Augmedics plans to complete R&D and conduct pre-clinical and clinical trials of The ViZOR, and to pursue 510(k) clearance from the U.S. FDA. Future product development includes integrating sensors to collect surgical data and applying deep learning to provide suggestions, alerts and other intraoperative assistance. The company has received industry honors and previously raised seed financing from the TerraLab incubator (an incubator of the Israeli Innovation Authority). Financially, it recently secured an $8.3 million Series A to advance regulatory and commercialization efforts.

• Lumere

  Participated · Equity · Jun 2016

  Lumere provides evidence-based analytics and services to help health systems reduce unwarranted and costly clinical variation. Its proprietary data and research support physician decision-making and product selection across the patient journey. The company says health systems in more than 40 states use its data and that it has helped over 650 healthcare facilities since 2012. Lumere’s offerings are designed to bring evidence and analytics closer to the individual physician, including tools to support case planning. The firm reports its work has helped health systems save millions in supply and drug spend while improving patient outcomes. Lumere plans to use new capital to develop and expand service offerings that enable evidence-led change at health systems nationwide. Procured Health provides technology and data-driven solutions designed to improve patient care while eliminating wasteful spending. Its core offerings address all aspects of clinical spend management, including opportunity identification, clinical decision making, contracting, utilization, and performance management. The company works with top-ranked health systems such as Stanford Health Care, Vanderbilt University Medical Center, Legacy Health, St. Joseph’s Health, and Johns Hopkins. Led by co-founder and CEO Hani Elias, JD, MPH, Procured Health intends to use new funding to expand its reach and to advance its solutions. The company announced a $10M funding round to support these plans. Procured Health develops web-based solutions to improve evaluation and purchasing of medical products by progressive healthcare providers. Its offerings include a comparative device-information platform and a product-evaluation workflow solution. The company says its tools leverage data science, market intelligence, and clinical insights to help members understand industry dynamics, identify competition, discover opportunities, and accelerate decision-making and implementation. Led by CEO Hani Elias, Procured Health targets healthcare organizations seeking more efficient product assessment and procurement processes. The company was actively hiring as of the article date. Procured Health offers a web-based application that enables hospitals and physicians to discover, compare and professionally review medical devices, with the stated aim of driving down device-related hospital spend. The product is positioned as a Bloomberg/Yelp‑style network for hospitals where clinicians can leave detailed, head‑to‑head reviews rather than simple star ratings. The company graduated from Blueprint Health’s accelerator and entered private beta, testing its network and pilot program with five healthcare systems, including three top-tier academic institutions. Procured is planning a full-scale launch in early 2013 and intends to scale its team and continue product development using the seed proceeds. The founders — Hani Elias (CEO), Eric Meizlish and Will Danford — built the company after identifying pervasive adoption barriers for lower-cost, effective devices while consulting with device manufacturers.

No current team members are available.